SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 5 — Focused Visit (Follow-up) — Zelda Fitzgerald — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientZelda Fitzgerald
Date of birth1900-07-24
IdentifiersMRN HR-ET004-SYN-TD; SSN (made up) 000-04-8712
Document date1930-08-10
AuthorMargot Ellery, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Three-month review: lithium, thyroid, kidney and metabolic checks, and the diagnosis reviewed. [S]

History of Present Illness

Ms. Fitzgerald returns three months after her first visit, fasting for her blood tests. She stopped risperidone eight weeks ago and takes aripiprazole 10 mg each morning and lithium 300 mg twice daily. She had a few days of mild inner restlessness in the first week of the switch, which passed. Her period returned in mid-July, five weeks after the switch, and again this month. She has had no manic, depressive, or psychotic symptoms since the spring and sleeps eight hours. She dances about three hours a day and eats to the dietitian's plan. Since the last visit, with her consent, her roommate and her own journal have filled in the weeks before the admission: the sleeplessness, rapid speech and grand plans came first, for about three weeks, and the voice and the belief she was being watched began only in the last week before admission and ended with the mania. She has had no thoughts of suicide or self-harm. [S]

ElementDetail
MedicinesLithium 300 mg twice daily; aripiprazole 10 mg daily; risperidone stopped eight weeks ago
PeriodsReturned in mid-July; regular since
Course of the episodeManic symptoms for about three weeks before any psychotic symptoms, which ended with them
MoodSteady; PHQ-9 4; item 9 scored 0
DanceAbout three hours a day, eating to plan

Review of Systems

SystemResultFinding
ConstitutionalNegativeEnergy good; weight up 1.4 kg, as planned
GenitourinaryNegativePeriods regular since July; no increased urination
EndocrineNegativeNo thirst, heat or cold intolerance, or breast discharge
NeurologicalNegativeRestlessness in the first week of the switch resolved; faint tremor when tired
PsychiatricNegativeMood steady; no manic or psychotic symptoms; no thoughts of suicide or self-harm

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Risperidone 2 mg oral tablet, one tablet by mouth at bedtime (started in hospital)One tablet by mouth at bedtimeOral route1930-04-20 to 1930-06-08completedS
Lithium carbonate 300 mg oral capsule, one capsule by mouth twice dailyOne capsule by mouth twice dailyOral route1930-05-18activeS
Risperidone 1 mg oral tablet, one tablet by mouth at bedtime for one week, then stopOne tablet by mouth at bedtime for one weekOral route1930-06-08 to 1930-06-15completedS
Aripiprazole 10 mg oral tablet, one tablet by mouth once dailyOne tablet by mouth once dailyOral route1930-06-08activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1930-08-10Body height165cmS
1930-08-10Body weight51.6kgS
1930-08-10Body mass index (BMI) [Ratio]19kg/m2S
1930-08-10Systolic blood pressure108mm[Hg]S
1930-08-10Diastolic blood pressure68mm[Hg]S
1930-08-10Heart rate70/minS
1930-08-10Respiratory rate14/minS
1930-08-10Body temperature36.6CelS
1930-08-10Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1930-08-10Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
1930-08-10Potassium [Moles/volume] in Serum or Plasma4.2mmol/L3.5-5.1 mmol/LNormalS
1930-08-10Creatinine [Mass/volume] in Serum or Plasma0.8mg/dL0.59-1.04 mg/dLNormalS
1930-08-10Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1925)/1.73 sq M102mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1930-08-10Lithium [Moles/volume] in Serum or Plasma0.74mmol/LMaintenance target 0.6 to 0.8 mmol/L; above 1.2 mmol/L is above the therapeutic rangeNormalS
1930-08-10Thyrotropin [Units/volume] in Serum or Plasma2.9m[IU]/L0.45-4.5 mIU/LNormalS
1930-08-10Calcium [Mass/volume] in Serum or Plasma9.6mg/dL8.6-10.2 mg/dLNormalS
1930-08-10Prolactin [Mass/volume] in Serum or Plasma14ng/mL4.8-23.3 ng/mLNormalS
1930-08-10Fasting glucose [Mass/volume] in Serum or Plasma86mg/dL70-99 mg/dLNormalS
1930-08-10Hemoglobin A1c/Hemoglobin.total in Blood5.1%Below 5.7% is normal; 5.7 to 6.4% prediabetesNormalS
1930-08-10Cholesterol [Mass/volume] in Serum or Plasma174mg/dL<=199 mg/dLNormalS
1930-08-10Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation94mg/dL<=129 mg/dLNormalS
1930-08-10Cholesterol in HDL [Mass/volume] in Serum or Plasma62mg/dL>=50 mg/dLNormalS
1930-08-10Triglyceride [Mass/volume] in Serum or Plasma82mg/dL<=149 mg/dLNormalS
1930-08-10Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]4{score}S

Physical Exam

Vital signs recorded on 1930-08-10; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 51.6 kg, BMI 19.0; blood pressure 108/68, pulse 70
NeckThyroid not enlarged
NeurologicalFaint fine postural tremor; no akathisia, rigidity, or abnormal movements
PsychiatricEuthymic; organized; no psychotic or manic features

Problems

ProblemClinical statusVerificationCodeProvenance
First episode of psychosis with marked mood symptoms: about three weeks of little sleep, rapid speech, racing thoughts, grandiose plans and very long training days, then a voice commenting on her dancing and a belief that she was being watched and tested; tearful low mood since discharge. Diagnosis provisional; differential: bipolar I disorder with psychotic features, schizoaffective disorder (bipolar type), and schizophreniform disorder or schizophrenia, depending on whether the psychosis ever occurred apart from the mood symptoms. Synthetic modern episode linked to her documented first hospitalizationresolvedprovisional F29S — Synthetic modern coding of the documented first breakdown. Unspecified psychosis is coded until the course shows how the psychosis relates to the mood symptoms; superseded at the three-month visit.
Bipolar I disorder, most recent episode manic with psychotic features, in full remission: the working diagnosis at three months, when her history, her journal, and her roommate's account (given with her consent) showed that the voice and the belief she was watched began only after weeks of manic symptoms and ended with them, with no psychosis since. Remains provisional: it would be revised to schizoaffective disorder if psychosis ever lasted two weeks or more without a mood episode. Synthetic modern episode linked to the documented breakdown and its retrospective interpretationsactiveprovisional F31.74S — Synthetic modern diagnosis made from the course; the historical diagnoses stay in the claims.
Secondary amenorrhea: no periods for about four months before admission, during very heavy dance training at a low weight (BMI 18.7), with prolactin raised on risperidone; pregnancy test negativeresolvedconfirmed N91.1S — Synthetic presenting finding linked to her documented training; resolved when her periods returned.
Acute viral gastroenteritis (vomiting and watery diarrhea for two days, roommate with the same illness), with mild dehydration; resolvedresolvedconfirmed A08.4S — Synthetic acute infection; not a historical claim.
Lithium level above the therapeutic range (1.4 mmol/L) during dehydration, with nausea and a worse fine tremor, without confusion or unsteadiness; lithium held and restarted; resolvedresolvedconfirmed T43.595AS — Synthetic medication adverse effect at a prescribed dose; ICD-10-CM classifies lithium salts with the other antipsychotics and neuroleptics.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
Medication safetyAntipsychotic dose, adherence, and responseEvery visitCompleted todayAripiprazole 10 mg for eight weeks; full adherence; in remission
SurveyManic, depressive, and psychotic symptoms, and early warning signsEvery visitCompleted todayNo manic, depressive, or psychotic symptoms; the history of the episode clarified
ExaminationAkathisia, parkinsonism, and sedationEvery visit in the first months and after any dose changeCompleted todayMild restlessness in the first week of the switch, resolved; none now
ExaminationWeight and BMIEvery visit for 6 months after starting or changing an antipsychotic (CMID: baseline, 4, 8, and 12 weeks, then quarterly)Deferred51.6 kg (BMI 19.0) today, up 1.4 kg since the switch, as she and the dietitian planned. The weight check due four weeks after the switch to aripiprazole was missed because no visit fell then; no harm resulted, since the gain was intended and modest. Corrective action: the care coordinator records her weight at the monthly meeting until six months after the switch
ExaminationBlood pressureBaseline, 12 weeks, then yearlyCompleted today108/68
LaboratoryFasting glucose and A1cBaseline, 12 weeks to 4 months, then yearlyCompleted todayFasting glucose 86 mg/dL; A1c 5.1%; sixteen weeks after the antipsychotic was started, within the APA's four months; yearly from now
LaboratoryFasting lipid panelBaseline, 12 weeks to 4 months, then yearlyCompleted todayTotal cholesterol 174, LDL 94, HDL 62, triglycerides 82 mg/dL; yearly from now
LaboratoryProlactinWhen there are symptoms of high prolactin, such as missed periodsCompleted today14 ng/mL, normal, eight weeks after the switch; periods back
LaboratoryLithium level (12-hour trough)5 to 7 days after starting and after any change until stable, then every 3 to 6 monthsCompleted today0.74 mmol/L
LaboratoryCreatinine and eGFR on lithiumBaseline, every 2 to 3 months for 6 months, then every 6 to 12 monthsCompleted todayCreatinine 0.80 mg/dL, eGFR 102; sodium 140, potassium 4.2 mmol/L
LaboratoryTSH on lithiumBaseline, once or twice in the first 6 months, then every 6 to 12 monthsCompleted today2.9 mIU/L, from 2.1
LaboratoryCalcium on lithiumBaseline, then yearlyCompleted today9.6 mg/dL; yearly from now
Medication safetyLithium side effects and sick-day rulesAt the start and every visitCompleted todayFaint tremor only; no thirst or increased urination
Medication safetyPregnancy prevention on lithium; valproate avoidedBefore starting and at each visit until a reliable method is in placeCompleted todayCounseling repeated; she chose a levonorgestrel intrauterine system at the preventive visit
SurveyDepression measure (PHQ-9)Monthly during acute treatment, every 2 to 4 weeks in continuation, then periodicallyCompleted todayPHQ-9 4, item 9 scored 0; the care coordinator's monthly check between visits was in the low range
SurveySuicide-risk review, safety plan, lethal means, and the 988 Suicide & Crisis LifelineEvery visitCompleted todayNo thoughts of suicide or self-harm; safety plan current
Self-managementSleepEvery visitCompleted todayEight hours at regular times
Self-managementEating, exercise, and periodsEvery visit while periods are absent or weight is lowCompleted todayPeriods regular; dancing about three hours a day; eating to plan
Self-managementCoordinated specialty care engagementOngoing, for up to two to three yearsCompleted todayTherapist every two weeks; peer specialist monthly; writing and dancing again

Goal progress:

Guideline basis: Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder (2018); The CANMAT and ISBD Guidelines for the Treatment of Bipolar Disorder: Summary and a 2023 Update of Evidence (2023); The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia, Third Edition (2020); Consensus development conference on antipsychotic drugs and obesity and diabetes (2004); Recovery After an Initial Schizophrenia Episode (RAISE): coordinated specialty care for first-episode psychosis (2026); U.S. Selected Practice Recommendations for Contraceptive Use, 2024 (2024); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)

Follow-up: Preventive visit in five weeks for a long-acting contraceptive. Six-month review with lithium level, creatinine, TSH, and the AIMS. Care coordinator monthly. Next scheduled visit 1930-09-14: periodic adult preventive visit with contraception. [S]